6533b7dcfe1ef96bd1271e4b
RESEARCH PRODUCT
Heteroaromatic Inhibitors of the Astacin Proteinases Meprin α, Meprin β and Ovastacin Discovered by a Scaffold-Hopping Approach.
Mirko BuchholzChristian JägerStefanie GeisslerDaniel RamsbeckKathrin TanDagmar SchlenzigWalter StöckerHagen Körschgensubject
ScaffoldTertiary amineStereochemistryCell SurvivalAntineoplastic Agentsscaffold hoppingMatrix metalloproteinaseScaffold hoppinghydroxamate01 natural sciencesBiochemistryHydrocarbons AromaticmetalloproteinasesStructure-Activity RelationshipmeprinVery Important PaperDrug DiscoveryTumor Cells CulturedHumansProtease InhibitorsGeneral Pharmacology Toxicology and PharmaceuticsAminesPharmacologyDose-Response Relationship DrugMolecular StructureFull Paper010405 organic chemistryChemistryOrganic ChemistryMetalloendopeptidasesFull PapersovastacinRecombinant Proteinsheteroaromatics0104 chemical sciences010404 medicinal & biomolecular chemistryMetalloproteasesMolecular MedicineAstacinDrug Screening Assays AntitumorSelectivitydescription
Abstract Astacin metalloproteinases, in particular meprins α and β, as well as ovastacin, are emerging drug targets. Drug‐discovery efforts have led to the development of the first potent and selective inhibitors in the last few years. However, the most recent compounds are based on a highly flexible tertiary amine scaffold that could cause metabolic liabilities or decreased potency due to the entropic penalty upon binding to the target. Thus, the aim of this study was to discover novel conformationally constrained scaffolds as starting points for further inhibitor optimization. Shifting from flexible tertiary amines to rigid heteroaromatic cores resulted in a boost in inhibitory activity. Moreover, some compounds already exhibited higher activity against individual astacin proteinases compared to recently reported inhibitors and also a favorable off‐target selectivity profile, thus qualifying them as very suitable chemical probes for target validation.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-12-23 | ChemMedChem |